The Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD) held its fifth meeting from 25-29 November 2024. The main objectives of the 5th SAGE IVD meeting were to provide recommendations for the next edition of the WHO Model List of Essential In-vitro Diagnostics (the EDL 5) and to review progress on the development of national EDLs.
On the first day, the EDL Secretariat hosted a public webinar. Online participants submitted questions and comments during the Q&A session. To watch the recordings please click on the following links:
5th SAGE IVD meeting Open Session webinar-20241125_093735-Meeting Recording.mp4
- Welcoming remarks (due to technical issues on the room, audio starts at 10m19s
- Introduction to the 5th SAGE IVD meeting Objective
- Introduction to the SAGE IVD and its members
- Overview of the WHO model list of essential in vitro diagnostics (EDL): scope and methodology for its review and update
- What is new for the EDL 5
- WHO essential diagnostic tests for bacterial and fungal infections and AMR
- EDL for Emergencies and Humanitarian Crises
5th SAGE IVD meeting Open Session webinar-20241125_105907-Enregistrement de la réunion.mp4
- Update on National EDLs
- The WHO Model Lists of Essential Medicines (EML) and its relationship with the EDL
- The WHA 76.5 resolution on strengthening diagnostics capacity
- MeDevIS, the UHC Compendium and the electronic EDL: improving access to diagnostic tools
- WHO Diagnostics Task Force and the Diagnostics Consortium
- Q&A session
WHO launched the first edition of the Model List of Essential In Vitro
Diagnostics (EDL) in May 2018. This was followed by three further editions, in 2019, 2021 and 2023. The goal of the EDL is to help countries advance UHC,
address health emergencies, and promote healthier populations by supporting IVD
policy development to improve people's access to IVD testing and clinical
laboratory services.
Draft agenda
| Time | Open session | Speaker |
|---|---|---|
| 09:00 – 09:05 | Welcoming remarks | Dr Yukiko Nakatani Assistant Director-General Access to Medicines and Health Products Division WHO |
| 09:05 – 09:10 | Introduction to the 5th SAGE IVD meeting objectives | Prof Francis Moussy EDL Secretariat lead Medical Devices and In Vitro Diagnostics WHO |
| 09:10 – 09:30 | Introduction to SAGE IVD and its members | |
| 09:30 – 09:50 | Overview of the WHO model list of essential in vitro diagnostics (EDL): scope and methodology for its review and update | Dr Ana Aceves Capri Technical Officer Medical Devices and In Vitro Diagnostics WHO |
| 09:50 – 10:00 | What is new for EDL 5? | |
| 10:00 – 10:15 | WHO essential diagnostic tests for bacterial and fungal infections and AMR | Dr Sriram Raghu Scientist Antimicrobial resistance Division WHO |
| 10:15 – 10:30 | EDL for Emergencies and Humanitarian Crises | Dr Philomena Raftery Senior Technical Officer Health Emergencies Programme WHO |
| 10:30 – 11:00 | Coffee break | |
| 11:00 – 11:30 | Update on National EDLs | Prof Francis Moussy EDL Secretariat Lead, MDD, WHO Dr Antonio Villanueva Senior Advisor on Healthcare Policy ERIA |
| 11:30 – 11:40 | The WHO Model Lists of Essential Medicines (EML) and its relationship with the EDL | Dr Bernadette Cappello Technical Officer EML Secretariat WHO |
| 11h40 – 11h50 | MeDevIS, the UHC Compendium and the electronic EDL: improving access to diagnostic tools | MSc Adriana Velazquez Team lead Medical Devices and In Vitro Diagnostics WHO |
| 11:50 – 12:00 | The WHA 76.5 resolution on strengthening diagnostics capacity and the WHO Diagnostics Task Force | |
| 12:00 – 13:00 | Discussion/comments from stakeholders | Stakeholders |
| End of open session |
For any further queries please contact WHO at EDLSecretariat@who.int. Please visit the WHO In vitro diagnostics website.
Disclaimer: By submitting this registration form, you hereby confirm your consent to the World Health Organization (WHO) collecting and processing your personal data (including your name, institutional affiliation, and email address) in accordance with WHO’s personal data protection framework for event registration and managing attendance, event follow-up, contacting you about future events, and preparing statistics of global event participation by region. Please note that a recording of the event may be made publicly available, for example on the WHO website.